A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma

• DOI: 10.1097/sla.0b013e3181fd271c
• Publication Date: 2011-01-07T08:03:32Z
• Authors: Lutz Eric; Charles J. Yeo; Keith D. Lillemoe; Barbara Biedrzycki; Barry Kobrin; Joseph Herman; Elizabeth Sugar; Steven Piantadosi; John L. Cameron; Sara Solt; Beth Onners; Irena Tartakovsky; Miri Choi; Rajni Sharma; Peter B. Illei; Hruban Ralph H.; Ross A. Abrams; Dung Le; Jaffee Elizabeth; Dan Laheru
• Keywords: FOLFIRINOX; Chemoradiotherapy; Clinical endpoint

Surgical resection provides the only possibility of cure for pancreas cancer. A standard adjuvant approach has not been established. We tested safety and efficacy a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy administered in patients with resected pancreatic adenocarcinoma.A single institution phase II study 60 adenocarcinoma was performed. Each treatment consisted total 5 × 108 GM-CSF-secreting cells distributed equally among 3 lymph node regions. The first 8 to 10 weeks after surgical resection. Subsequently, received 5-FU based chemoradiation. Patients who remained disease-free completion chemoradiotherapy treatments 2 4, each 1 month apart. fifth final booster 6 months fourth immunotherapy. primary endpoint disease free survival secondary endpoints were overall toxicity, induction mesothelin specific T cell responses.The median is 17.3 (95% CI, 14.6-22.8) 24.8 21.2-31.6). administration well tolerated. In addition, post-immunotherapy mesothelin-specific CD8+ HLA-A1+ HLA-A2+patients correlates survival.An integrated chemoradiation safe demonstrates an that compares favorably published data These suggest additional boost immunotherapies given at regular intervals beyond year postsurgery should be future studies, provide rationale conducting multicenter study.